LX-4211 CAS 1018899-04-1

Product Description:

Product Name: LX-4211 CAS NO: 1018899-04-1

Synonyms:

Sotagliflozin;

(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;

Chemical & Physical Properties:

Appearance: Powder

Assay :≥99.0%

Density: 1.37±0.1 g/cm3 (Predicted)

Boiling Point: 607.9±55.0℃ (Predicted)

PKa: 12.87±0.70 (Predicted)

Flash Point: 321.4±31.5℃

Vapor Pressure: 0.0±1.8 mmHg at 25℃

Index of Refraction: 1.642

Sogliazin LX-4211 is a dual SGLT1/SGLT2 inhibitor with a novel hypoglycemic mechanism. Previous studies have demonstrated its efficacy in both type 1 diabetes and type 2 diabetes. In three pivotal multicenter phase Ⅲ trials of sorglipin as adjuvant insulin therapy in 1Chemicalbook diabetes mellitus, the sorglipin group met the endpoint without severe hypoglycemia or other SAEs during the study period. This provides a clinical basis for the net approval of Soglar as an adjuvant insulin therapy in the treatment of type 1 diabetes. Soglijin LX-4211 is a novel oral diabetes drug developed by Sanofi and Lescon Pharmaceuticals. As a dual inhibitor of SGLT-1 and SGLT-2, the drug can reduce postprandial blood glucose, increase GLP-1 and promote urinary glucose excretion.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.